- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT01255163
A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease
A Pilot Study of Exendin-4 in Alzheimer s Disease
Background:
Exendin-4 (or Exenatide) is a medication currently used to treat diabetes that has shown promising results in animal and cellular models of Alzheimer's disease. It is possible that Exendin-4 may be a treatment for Alzheimer's disease, which involves the gradual deterioration and death of neurons. Researchers are interested in studying the safety and comparing the effects of Exendin-4 with placebo on cognitive performance, clinical progression of dementia, various chemicals measured in blood and cerebrospinal fluid, and brain MRI, in individuals with early-stage Alzheimer's disease or mild cognitive impairment.
Objectives:
To determine the safety and tolerability of twice daily administration of Exendin-4, as well as to acquire preliminary evidence for effects on cognitive performance, clinical progression of dementia, various chemicals measured in blood and cerebrospinal fluid, and brain MRI, in individuals with early-stage Alzheimer's disease or mild cognitive impairment.
Eligibility:
Individuals at least 60 years of age who have objective evidence of early-stage Alzheimer's disease or mild cognitive impairment in screening testing.
Design:
- Participants will be screened.
- Following the telephone screening, two in-person screening visits to determine eligibility.
- The screening visit will involve a medical history and neurological examination, tests of memory and cognition, a lumbar puncture, collection of blood and saliva samples, and brain Magnetic Resonance Imagine (MRI) studies. Participants will be required to appoint a Durable Power of Attorney for research and medical care during this protocol.
- Eligible participants will be divided into two groups (double-blind randomization). One group will receive Exendin-4 SC twice daily, and the other will receive a placebo. Participants will keep a medication diary and will be scheduled for additional study visits 1 and 2 weeks after the start of the treatment.
- Participants will have regular followup visits with blood tests, cognitive tests, imaging studies, and other examinations 6, 12, and 18 months after the start of the treatment. Another lumbar puncture may be performed optionally at the 18-month followup visit.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21224
- National Institute on Aging, Clinical Research Unit
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
- INCLUSION CRITERIA:
- Age > 60
- Clinical Dementia Rating (global CDR) of 0.5 or 1. Memory box score must be at least 0.5.
- Mini Mental Status Exam (MMSE) > 20
- Clinical diagnosis of (amnestic or mixed) MCI or early AD and Memory deficit on neuropsychological or clinical testing.
- Hamilton Depression Scale score of less than or equal to 12 on the 17-item scale
- CSF A beta 42 < 192 (+- 10%) pg/ml (given an intra-subject laboratory variability ~ 10%)
Medications stable for at least 4 weeks prior to screening. In particular:
- Participants may take stable doses of antidepressants, chronic anxiolytics or sedative hypnotics, if started at least 4 weeks or longer prior to screening
- Cholinesterase inhibitors and/or memantine are allowable, if started at least 4 weeks prior to screening
- Participants will not be asked to discontinue medications without permission from their primary care provider (PCP) or specialist.
- Fluency in English
- At the time of enrollment, participants must have the ability to provide informed consent and make health care decisions.
- An informant or caregiver who has frequent contact with the participant (e.g. an average of 10 hours per week or more) must be appointed to serve as Durable Power of Attorney (DPA) for research and medical care at NIA, accompany the participant to clinic visits and provide historical information regarding the participant s cognitive status, and assist participants with/administer injections of the investigational medication.
- Good general health with no additional disease states that could interfere with the study.
EXCLUSION CRITERIA:
- Other significant neurological disease of the Central Nervous System (such as Parkinson s disease, atypical Parkinsons disease, Multi-infarct Dementia, Frontotemporal Dementia, Huntington s disease, Normal Pressure Hydrocephalus, brain tumor, Progressive Supranuclear Palsy, Epilepsy, Subdural Hematoma or Multiple Sclerosis)
- A history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities
- Positive RPR or HIV
- Abnormal PT/PTT and INR (1.5 standard deviation over the upper normal limit) increasing the risk for LP related bleeding/hematoma; platelet count <100,000/microliters.
- Anti-coagulant therapy (such as coumadin). Aspirin up to 325 is allowed.
- Investigators unable to obtain CSF, failure of Lumbar Puncture after a limited number of unsuccessful attempts).
- History of psychiatric disease with significant impairment in thought processes (e.g. schizophrenia, bipolar disease, psychosis). Participants who develop psychiatric conditions necessitating treatment after their enrollment will not be dropped from the study. The high incidence of late-onset depression and anxiety among individuals with MCI and AD requires that participants with depression, and/or anxiety should not be excluded from the cohort to maintain the ecological validity of the results.
- Current abuse of alcoholic beverages (> 7 in women and >14 in men) or substance abuse.
- Known diagnosis of diabetes at the time of enrollment or new diagnosis of diabetes based on the findings of elevated fasting blood glucose (= or >126 mg/dl) and/or the oral glucose tolerance test at screening (>200 mg/dl at two hours).
- Severe renal impairment (creatinine clearance <30 ml/min) or end-stage renal disease. Individuals with moderate renal impairment (creatinine clearance 30 to 50 ml/min) may be enrolled in the study, but their BUN and Creatinine will be monitored during each visit after drug initiation and extra safety visits will be conducted at 3, 9, and 15 months.
- Current or previous treatment with Exendin-4 (Exenatide, trade name Byetta.)
- History of pancreatitis, active upper GI, hepatic or gallbladder disease
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- History of repeated hypoglycemia
- Body mass index (BMI) < 18 on enrollment (given the expected weight loss caused by Exendin-4 and dementia). In the BLSA, participants with age > 65 had a mean BMI of 25.8 with SD of 3.9 Exendin-4 has been shown to cause an average 5.3 kg weight loss, with 95% CI: 6 to 4.5 kg (126).
- Allergy to Exendin-4 or to substances in the injection pen (metacresol, mannitol, glacial acetic acid, sodium acetate trihydrate, water for injection).
- Participation in other studies of investigational treatments for Alzheimer s disease in the last year.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: Exendin-4
Exenatide 5 mcg or 10 mcg SC twice daily
|
Exenatide 5 mcg or 10 mcg SC twice daily
Другие имена:
|
Плацебо Компаратор: Placebo
Placebo SC twice daily
|
Placebo SC twice daily
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Number of Participants With Incidence of Nausea
Временное ограничение: 18 months
|
Tolerability of exenatide (nausea is the most common expected adverse event of exenatide)
|
18 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Mini Mental State Examination (MMSE)
Временное ограничение: 18 months
|
Scale range: 0 - 30 points (higher is better)
|
18 months
|
Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog70)
Временное ограничение: 18 months
|
Alzheimer's dementia scale cognitive sub-scale range: 0 - 70 points (higher is worse)
|
18 months
|
Clinical Dementia Rating (CDR) Global Score
Временное ограничение: 18 months
|
Clinical Dementia Rating global score range: 0 (no dementia); 0.5 (Mild Cognitive Impairment); 1 (mild dementia); 2 (moderate dementia); 3 (severe dementia).
Higher is worse.
|
18 months
|
Clinical Dementia Rating (CDR) Sum of Boxes
Временное ограничение: 18 months
|
Sum of the Clinical Dementia Rating "boxes" (memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care).
Each box is rated as 0, 0.5, 1, 2 or 3. Range for the sum of boxes is 0 - 18. Higher scores reflect a greater severity of dementia.
|
18 months
|
Cerebrospinal Fluid (CSF) Total Tau
Временное ограничение: 18 months
|
Total Tau measured in CSF using Luminex xMAP technology and INNO-BIA Alz Bio3 kits (Research Use Only) provided by Fujirebio
|
18 months
|
Cerebrospinal Fluid phospho181-tau (CSF p181-tau)
Временное ограничение: 18 months
|
p-181-Tau measured in CSF using Luminex xMAP technology and INNO-BIA Alz Bio3 kits (Research Use Only) provided by Fujirebio
|
18 months
|
Cerebrospinal Fluid Amyloid-beta 42 (CSF Abeta42)
Временное ограничение: 18 months
|
Abeta42 peptide measured in CSF using Luminex xMAP technology and INNO-BIA Alz Bio3 kits (Research Use Only) provided by Fujirebio
|
18 months
|
Body Mass Index (BMI)
Временное ограничение: 18 months
|
Body Mass Index defined as a person's weight in kilograms (kg) divided by his or her height in meters squared.
|
18 months
|
Соавторы и исследователи
Публикации и полезные ссылки
Общие публикации
- Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol. 2011 Feb;10(2):187-98. doi: 10.1016/S1474-4422(10)70277-5. Epub 2010 Dec 10. Erratum In: Lancet Neurol. 2011 Feb;10(2):115.
- Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J Clin Invest. 2012 Apr;122(4):1339-53. doi: 10.1172/JCI57256.
- Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D. A Pilot Study of Exenatide Actions in Alzheimer's Disease. Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950.
- Muscogiuri G, DeFronzo RA, Gastaldelli A, Holst JJ. Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Trends Endocrinol Metab. 2017 Feb;28(2):88-103. doi: 10.1016/j.tem.2016.10.001. Epub 2016 Oct 27.
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Психические расстройства
- Заболевания головного мозга
- Заболевания центральной нервной системы
- Заболевания нервной системы
- Нейрокогнитивные расстройства
- Нейродегенеративные заболевания
- Слабоумие
- Таупатии
- Когнитивные расстройства
- Болезнь Альцгеймера
- Когнитивная дисфункция
- Гипогликемические агенты
- Физиологические эффекты лекарств
- Гормоны
- Гормоны, заменители гормонов и антагонисты гормонов
- Агенты против ожирения
- Инкретины
- Эксенатид
Другие идентификационные номера исследования
- 100423
- 10-AG-0423
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Exendin-4 SC
-
StemCells, Inc.ПрекращеноТравма шейного отдела спинного мозга | Травма позвоночника | Травма шейного отдела позвоночникаСоединенные Штаты, Канада
-
argenxРекрутингЩитовидная болезнь глазСоединенные Штаты
-
Hanmi Pharmaceutical Company LimitedЗавершенныйДиабет 2 типаСоединенные Штаты
-
Hangzhou Sumgen Biotech Co., Ltd.РекрутингСистемная красная волчанка (СКВ)Китай
-
argenxРекрутингЩитовидная болезнь глазСоединенные Штаты
-
StemCells, Inc.ПрекращеноВозрастная дегенерация желтого пятна | Географическая атрофияСоединенные Штаты
-
ViiV HealthcareGlaxoSmithKlineЕще не набираютВИЧ-инфекцииСоединенные Штаты
-
AkesoРекрутинг
-
argenxАктивный, не рекрутирующийГенерализованная миастения грависСоединенные Штаты, Бельгия, Чехия, Грузия, Германия, Венгрия, Италия, Япония, Нидерланды, Польша, Российская Федерация, Испания
-
Quanta Dialysis Technologies LtdАктивный, не рекрутирующий